Grifols S.A (G0FB) - Net Assets
Based on the latest financial reports, Grifols S.A (G0FB) has net assets worth €7.60 Billion EUR (≈ $8.88 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.77 Billion ≈ $23.11 Billion USD) and total liabilities (€12.17 Billion ≈ $14.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Grifols S.A (G0FB) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.60 Billion |
| % of Total Assets | 38.44% |
| Annual Growth Rate | 11.03% |
| 5-Year Change | 28.08% |
| 10-Year Change | N/A |
| Growth Volatility | 17.8 |
Grifols S.A - Net Assets Trend (2016–2024)
This chart illustrates how Grifols S.A's net assets have evolved over time, based on quarterly financial data. Also explore Grifols S.A assets under control for the complete picture of this company's asset base.
Annual Net Assets for Grifols S.A (2016–2024)
The table below shows the annual net assets of Grifols S.A from 2016 to 2024. For live valuation and market cap data, see market value of Grifols S.A.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
+14.55% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
-11.16% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
+3.81% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
+21.23% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
-1.84% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
+45.76% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
+29.24% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
-2.52% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Grifols S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €156.92 Million | 2.67% |
| Other Components | €5.73 Billion | 97.33% |
| Total Equity | €5.88 Billion | 100.00% |
Grifols S.A Competitors by Market Cap
The table below lists competitors of Grifols S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grg Metrology
SHE:002967
|
$1.99 Billion |
|
Vermilion Energy Inc.
TO:VET
|
$1.99 Billion |
|
Select Medical Holdings
NYSE:SEM
|
$1.99 Billion |
|
BRP Inc
TO:DOO
|
$1.99 Billion |
|
Dynex Capital Inc
NYSE:DX
|
$1.99 Billion |
|
RLX Technology Inc
NYSE:RLX
|
$1.99 Billion |
|
Spartan Delta Corp
TO:SDE
|
$1.99 Billion |
|
HHC Changzhou Corp.
SHE:301061
|
$1.99 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grifols S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,368,376,000 to 5,883,727,000, a change of 515,351,000 (9.6%).
- Net income of 156,920,000 contributed positively to equity growth.
- Dividend payments of 962,000 reduced retained earnings.
- Other factors increased equity by 359,393,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €156.92 Million | +2.67% |
| Dividends Paid | €962.00K | -0.02% |
| Other Changes | €359.39 Million | +6.11% |
| Total Change | €- | 9.60% |
Book Value vs Market Value Analysis
This analysis compares Grifols S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.76x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.24x to 0.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.31 | €6.60 | x |
| 2018-12-31 | €6.15 | €6.60 | x |
| 2019-12-31 | €7.05 | €6.60 | x |
| 2020-12-31 | €7.46 | €6.60 | x |
| 2021-12-31 | €8.98 | €6.60 | x |
| 2022-12-31 | €9.04 | €6.60 | x |
| 2023-12-31 | €7.91 | €6.60 | x |
| 2024-12-31 | €8.65 | €6.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grifols S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.18%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 3.64x
- Recent ROE (2.67%) is below the historical average (9.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.66% | 13.47% | 0.40x | 2.72x | €173.31 Million |
| 2017 | 18.26% | 15.35% | 0.40x | 3.01x | €299.79 Million |
| 2018 | 14.12% | 13.30% | 0.36x | 2.95x | €174.09 Million |
| 2019 | 12.96% | 12.26% | 0.33x | 3.22x | €142.93 Million |
| 2020 | 13.88% | 13.28% | 0.35x | 2.99x | €198.15 Million |
| 2021 | 3.00% | 3.71% | 0.26x | 3.15x | €-426.86 Million |
| 2022 | 3.40% | 3.43% | 0.28x | 3.51x | €-404.71 Million |
| 2023 | 0.79% | 0.64% | 0.31x | 3.91x | €-494.52 Million |
| 2024 | 2.67% | 2.18% | 0.34x | 3.64x | €-431.45 Million |
Industry Comparison
This section compares Grifols S.A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $31,535,255,973
- Average return on equity (ROE) among peers: 9.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grifols S.A (G0FB) | €7.60 Billion | 14.66% | 1.60x | $1.99 Billion |
| Bayer AG NA (BAYN) | $33.17 Billion | 3.01% | 2.63x | $43.70 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $489.18 Million | -0.74% | 0.25x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $9.13 Billion | 20.61% | 0.45x | $10.18 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $35.02 Billion | 16.77% | 0.32x | $11.04 Billion |
| Sanofi (SNW2) | $74.35 Billion | 7.26% | 0.70x | $105.72 Billion |
| AstraZeneca PLC (ZEGA) | $37.06 Billion | 8.87% | 1.60x | $252.57 Billion |
About Grifols S.A
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more